Last updated: July 17, 2026

Application No. 17/911,461

PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION

Final Rejection

Filed

Sep 14, 2022

Priority

Mar 17, 2020 — provisional 62/990,721 +3 more

Examiner

CHEN, PO-CHIH

Art Unit

1621

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Cocrystal Pharma Inc.

OA Round

2 (Final)

Interview Optional

— +14.5% interview lift. Interview lift (+14.5%) is below the 15.0% threshold. A written response is recommended.

Based on 753 resolved cases, 2023–2026

Examiner Intelligence

CHEN, PO-CHIH View full profile →

Grants 74% — above average

Career Allowance Rate

559 granted / 753 resolved

+14.2% vs TC avg

Moderate +14% lift

Without

With

+14.5%

Interview Lift

resolved cases with interview

Typical timeline

2y 4m

Avg Prosecution

55 currently pending

Career history

801

Total Applications

across all art units

Statute-Specific Performance

§101

0.6%

-39.4% vs TC avg

§103

61.8%

+21.8% vs TC avg

§102

15.0%

-25.0% vs TC avg

§112

20.8%

-19.2% vs TC avg

Black line = Tech Center average estimate • Based on career data from 753 resolved cases

Prosecution Timeline

Sep 14, 2022

Application Filed

Oct 21, 2025

Non-Final Rejection mailed

Feb 23, 2026

Response Filed

Jun 01, 2026

Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

16/328,636

Patent 12678423

THERAPEUTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS AND COMPOSITION FOR TREATMENT

7y 0m to grant Granted Jul 14, 2026

17/268,063

Patent 12668573

Linker, Antibody-Drug Conjugate Including Same and Use Thereof

5y 4m to grant Granted Jun 30, 2026

17/780,969

Patent 12653787

A PHARMACEUTICAL ORAL DOSAGE FORM OF Q203

4y 0m to grant Granted Jun 16, 2026

18/296,742

Patent 12655114

IONIZABLE LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS

3y 2m to grant Granted Jun 16, 2026

18/428,190

Patent 12643916

PROBE RELATED REAGENTS AND METHODS

2y 4m to grant Granted Jun 02, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4

Expected OA Rounds

74%

Grant Probability

89%

With Interview (+14.5%)

2y 4m (~0m remaining)

Median Time to Grant

Moderate

PTA Risk

Based on 753 resolved cases by this examiner. Grant probability derived from career allowance rate.